Japan Tobacco
JT Group is a diversified consumer goods company with core activities in tobacco, pharmaceuticals, and processed food. The Group publishes integrated financial and sustainability reporting, operates enterprise-wide compliance and information security programs, and describes capabilities in pharmaceutical R&D and clinical development, product innovation for reduced-risk nicotine/tobacco formats, global supply‑chain management, and human-rights and sustainability governance.
Industries
Nr. of Employees
Very Large (1000+)
Patents
Method for displaying time-varying flavor as time-varying visual element, program, and information processing device
US-12501940-B2
View DetailsPower supply unit of aerosol generating device and aerosol generating device
US-12478099-B2
View Details
Method for displaying time-varying flavor as time-varying visual element, program, and information processing device
US-12501940-B2
View DetailsPower supply unit of aerosol generating device and aerosol generating device
US-12478099-B2
View DetailsProducts
Reduced‑risk nicotine/tobacco product portfolio
Range of product formats across combustibles and reduced‑risk segments including heated tobacco sticks, e‑vapor and modern oral products.
Reduced‑risk nicotine/tobacco product portfolio
Range of product formats across combustibles and reduced‑risk segments including heated tobacco sticks, e‑vapor and modern oral products.
Services
Drug discovery and clinical development across therapeutic areas; clinical trial execution and regulatory filing support.
Research, development and commercialisation support for combustible and reduced‑risk nicotine/tobacco product formats.
Design and implementation of group sustainability programs, human rights due diligence, supplier engagement, and community investment initiatives with impact measurement.
Drug discovery and clinical development across therapeutic areas; clinical trial execution and regulatory filing support.
Research, development and commercialisation support for combustible and reduced‑risk nicotine/tobacco product formats.
Design and implementation of group sustainability programs, human rights due diligence, supplier engagement, and community investment initiatives with impact measurement.
Expertise Areas
- Information security and IT governance
- Clinical development and regulatory submissions
- Pharmaceutical research and development
- Human rights due diligence and grievance systems
Key Technologies
- Cloud services security
- Vulnerability and penetration testing
- E‑learning and mobile training platforms
- Telematics and driver behaviour analytics
News & Updates
Consolidated financial results for the nine months ended September 30, 2025 (IFRS) and related investor presentation materials.
New drug application filed for a topical AhR‑modulating agent for pediatric atopic dermatitis in Japan.
Announcement that a license partner received acceptance of a new drug application for a topical JAK inhibitor in China.
Selected for CDP’s “A List” and recognised as a Supplier Engagement Leader for climate-related disclosure and supplier engagement.
GHG reduction targets validated by the Science Based Targets initiative, including 2030 operational targets and a Net‑Zero value chain ambition for 2050.
Certified as a Global Top Employer in external employer benchmarking.
Consolidated financial results for the nine months ended September 30, 2025 (IFRS) and related investor presentation materials.
New drug application filed for a topical AhR‑modulating agent for pediatric atopic dermatitis in Japan.
Announcement that a license partner received acceptance of a new drug application for a topical JAK inhibitor in China.
Selected for CDP’s “A List” and recognised as a Supplier Engagement Leader for climate-related disclosure and supplier engagement.
GHG reduction targets validated by the Science Based Targets initiative, including 2030 operational targets and a Net‑Zero value chain ambition for 2050.
Certified as a Global Top Employer in external employer benchmarking.